A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study

Zhigang Ren,Hong Luo,Zujiang Yu,Jingchao Song,Lan Liang,Ling Wang,Haiyu Wang,Guangying Cui,Yong Liu,Jin Wang,Qingquan Li,Zhaohai Zeng,Shengkun Yang,Guangzhong Pei,Yonghui Zhu,Wenbin Song,Wenquan Yu,Chuanjun Song,Lihong Dong,Chuansong Hu,Jinfa Du,Junbiao Chang
DOI: https://doi.org/10.1002/advs.202001435
IF: 15.1
2020-08-13
Advanced Science
Abstract:Coronavirus disease 2019 (COVID‐19) has spread worldwide. To date, no specific drug for COVID‐19 has been developed. Thus we performed this randomized, open‐label, controlled clinical trial (ChiCTR2000029853) in China. A total of 20 mild and common COVID‐19 patients were enrolled and randomly assigned to receive azvudine and symptomatic treatment (FNC group), or standard antiviral and symptomatic treatments (control group). The mean times of the first nucleic acid negative conversion (NANC) of 10 patients in the FNC group and 10 patients in the control group were 2.60 (SD 0.97; range 1–4) days and 5.60 (SD 3.06; range 2–13) days, respectively (p = 0.08). The mean times of the first NANC of 4 newly diagnosed subjects in the FNC group and 10 subjects in the control group were 2.50 (SD 1.00; range 2–4) days and 9.80 (SD 4.73; range 3–19) days, respectively (starting from the initial treatment) (p = 0.01). No adverse events occurred in the FNC group, while 3 adverse events occurred in the control group (p = 0.06). The preliminary results showed that FNC treatment in the mild and common COVID‐19 may shorten the NANC time versus standard antiviral treatment. Therefore, clinical trials of FNC treating COVID‐19 with larger sample size are warranted.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the efficacy and safety of Azvudine (FNC) tablets in the treatment of mild and common - type Coronavirus Disease 2019 (COVID - 19). Specifically, through a randomized, open - label, controlled clinical trial, the researchers aimed to explore whether Azvudine can shorten the time for patients' first nucleic acid test to turn negative compared with standard antiviral treatment, and to evaluate its safety. ### Research Background - **COVID - 19 Pandemic**: As of July 1, 2020, more than 10 million cases of COVID - 19 had been confirmed globally, and the death toll exceeded 500,000. At present, there are no specific drugs for COVID - 19. - **Characteristics of SARS - CoV - 2 Virus**: SARS - CoV - 2 is a typical enveloped single - stranded positive - strand RNA virus, belonging to the Betacoronavirus genus of the Coronaviridae family. RNA synthesis requires nucleosides and nucleotides as raw materials. - **Nucleoside - based Antiviral Drugs**: These drugs can inhibit the synthesis of viral DNA or RNA, thereby preventing virus replication. Azvudine is a dual - target nucleoside - based drug, which has significant broad - spectrum in - vitro antiviral effects against multiple viruses such as HIV, HCV, EV71 and HBV. Recent studies have shown that Azvudine also has strong antiviral activity against HCoV - OC43 and SARS - CoV - 2. ### Research Objectives - **Evaluate the Efficacy of Azvudine**: The primary outcome measures are the SARS - CoV - 2 nucleic acid negative conversion rate and the time to negative conversion. - **Evaluate the Safety of Azvudine**: Monitor adverse events in patients, including vital signs, laboratory test results, etc. ### Research Design - **Research Type**: Prospective, randomized, open - label, controlled clinical trial. - **Sample Selection**: A total of 28 mild and common - type COVID - 19 patients were screened, and finally 20 patients were included and randomly divided into the Azvudine group (FNC group, n = 10) and the control group (n = 10). - **Treatment Plan**: - **FNC Group**: Oral Azvudine tablets 5 mg/day (5 tablets at a time, once every night), and symptomatic treatment was carried out. - **Control Group**: Received standard antiviral treatment and symptomatic treatment. ### Main Results - **Nucleic Acid Negative Conversion Rate**: After 4 days of treatment, the nucleic acid negative conversion rate in the FNC group was 100%, while that in the control group was only 30% (p = 0.0013). After 6 days of treatment, the nucleic acid negative conversion rate in the FNC group was 100%, while that in the control group was 40% (p = 0.0011). - **Nucleic Acid Negative Conversion Time**: The average first nucleic acid negative conversion time in the FNC group was 2.60 days (SD 0.97), and that in the control group was 5.60 days (SD 3.06) (p = 0.08). For newly diagnosed patients, the average first nucleic acid negative conversion time in the FNC group was 2.50 days (SD 1.00), and that in the control group was 9.80 days (SD 4.73) (p = 0.01). - **Safety**: No adverse events occurred in the FNC group, while 3 adverse events occurred in the control group (p = 0.06). ### Conclusion Preliminary results show that Azvudine may shorten the nucleic acid negative conversion time in mild and common - type COVID - 19 patients and has good safety. Therefore, it is necessary to conduct clinical trials with a larger sample size to further verify these results.